{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:47:23Z","timestamp":1787068043324,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40257-023-00793-5","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:05:11Z","timestamp":1685696711000},"page":"753-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"24","author":[{"given":"Diana","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"793_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66:8\u201316. https:\/\/doi.org\/10.1159\/000370220.","journal-title":"Ann Nutr Metab"},{"issue":"6","key":"793_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393. https:\/\/doi.org\/10.1111\/all.13401.","journal-title":"Allergy"},{"key":"793_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-zReviews","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018. https:\/\/doi.org\/10.1038\/s41572-018-0001-zReviews.","journal-title":"Nat Rev Dis Primers"},{"issue":"10247","key":"793_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"3","key":"793_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","volume":"79","author":"ATM R\u00f8nnstad","year":"2018","unstructured":"R\u00f8nnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448-456.e30. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.017.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"793_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","volume":"131","author":"P Yaghmaie","year":"2013","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428\u201333. https:\/\/doi.org\/10.1016\/j.jaci.2012.10.041.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"793_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330. https:\/\/doi.org\/10.1016\/j.jid.2016.07.012.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"793_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1248\/bpb.b19-00088","volume":"43","author":"M Fujii","year":"2020","unstructured":"Fujii M. Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus. Biol Pharm Bull. 2020;43(1):12\u20139. https:\/\/doi.org\/10.1248\/bpb.b19-00088.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"793_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.22034\/iji.2019.80253","volume":"16","author":"M Furue","year":"2019","unstructured":"Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Pathogenesis of atopic dermatitis: current paradigm. Iran J Immunol. 2019;16(2):97\u2013107. https:\/\/doi.org\/10.22034\/iji.2019.80253.","journal-title":"Iran J Immunol"},{"key":"793_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","volume":"1027","author":"W David Boothe","year":"2017","unstructured":"David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21\u201337. https:\/\/doi.org\/10.1007\/978-3-319-64804-0_3.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"793_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI, Kantor R. The role of interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327\u201334. https:\/\/doi.org\/10.1016\/j.det.2017.02.005.","journal-title":"Dermatol Clin"},{"issue":"1","key":"793_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy Eur J Allergy Clin Immunol. 2020;75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"1","key":"793_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: sectin 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.023.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"793_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382. https:\/\/doi.org\/10.1111\/jdv.14891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"793_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: sectin 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"793_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"793_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.det.2018.12.007","volume":"37","author":"Y Renert-Yuval","year":"2019","unstructured":"Renert-Yuval Y, Guttman-Yassky E. What\u2019s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205\u201313. https:\/\/doi.org\/10.1016\/j.det.2018.12.007.","journal-title":"Dermatol Clin"},{"issue":"5","key":"793_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.017.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"793_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"793_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666X.2020.1858802","volume":"17","author":"C Tubau","year":"2021","unstructured":"Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021;17(1):15\u201325. https:\/\/doi.org\/10.1080\/1744666X.2020.1858802.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"793_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.13911","volume":"28","author":"M Moyle","year":"2019","unstructured":"Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756\u201368. https:\/\/doi.org\/10.1111\/exd.13911.","journal-title":"Exp Dermatol"},{"issue":"8","key":"793_CR22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","volume":"425","author":"M Ultsch","year":"2013","unstructured":"Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol. 2013;425(8):1330\u20139. https:\/\/doi.org\/10.1016\/j.jmb.2013.01.024.","journal-title":"J Mol Biol"},{"issue":"8","key":"793_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835\u201352. https:\/\/doi.org\/10.1080\/1744666X.2021.1940962.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"793_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.20344\/amp.11963","volume":"32","author":"T Torres","year":"2019","unstructured":"Torres T, Ferreira EO, Gon\u00e7alo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606\u201313. https:\/\/doi.org\/10.20344\/amp.11963.","journal-title":"Acta Med Port"},{"issue":"3","key":"793_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","volume":"150","author":"Y Miron","year":"2022","unstructured":"Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690\u2013700. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"793_CR26","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis Is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"793_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000448400","volume":"170","author":"SA Koppes","year":"2016","unstructured":"Koppes SA, Brans R, Ljubojevic Hadzavdic S, Frings-Dresen MHW, Rustemeyer T, Kezic S. Stratum corneum tape stripping: monitoring of inflammatory mediators in atopic dermatitis patients using topical therapy. Int Arch Allergy Immunol. 2016;170(3):187\u201393. https:\/\/doi.org\/10.1159\/000448400.","journal-title":"Int Arch Allergy Immunol"},{"issue":"11","key":"793_CR28","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/jdv.13160","volume":"29","author":"K Szegedi","year":"2015","unstructured":"Szegedi K, Lutter R, Res PC, et al. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015;29(11):2136\u201344. https:\/\/doi.org\/10.1111\/jdv.13160.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"793_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00403-004-0455-6","volume":"295","author":"T Tazawa","year":"2004","unstructured":"Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459\u201364. https:\/\/doi.org\/10.1007\/s00403-004-0455-6.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"793_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","volume":"137","author":"B Ungar","year":"2017","unstructured":"Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603\u201313. https:\/\/doi.org\/10.1016\/j.jid.2016.09.037.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"793_CR31","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.4049\/jimmunol.1100504","volume":"186","author":"MH Oh","year":"2011","unstructured":"Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;186(12):7232\u201342. https:\/\/doi.org\/10.4049\/jimmunol.1100504.","journal-title":"J Immunol"},{"key":"793_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pupt.2017.08.010","volume":"46","author":"R Zhu","year":"2017","unstructured":"Zhu R, Zheng Y, Dirks NL, et al. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. Pulm Pharmacol Ther. 2017;46:88\u201398. https:\/\/doi.org\/10.1016\/j.pupt.2017.08.010.","journal-title":"Pulm Pharmacol Ther"},{"key":"793_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"key":"793_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad022","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"2","key":"793_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534.","journal-title":"JAMA Dermatol"},{"key":"793_CR36","unstructured":"ClinicalTrials.gov. Long-term safety and efficacy study of lebrikizumab (ly3650150) in participants with moderate-to-severe atopic dermatitis (ADjoin). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392154. Accessed 4 Apr 2023."},{"key":"793_CR37","unstructured":"ClinicalTrials.gov. Study to assess the safety and efficacy of lebrikizumab (ly3650150) in adolescent participants with moderate-to-severe atopic dermatitis (ADore). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04250350. Accessed 4 Apr 2023."},{"key":"793_CR38","unstructured":"ClinicalTrials.gov. A study of lebrikizumab (LY3650150) on vaccine response in adults with atopic dermatitis (ADopt-VA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04626297. Accessed 4 Apr 2023."},{"issue":"8","key":"793_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748\u201356. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206719.","journal-title":"Thorax"},{"issue":"10","key":"793_CR40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781\u201396. https:\/\/doi.org\/10.1016\/S2213-2600(16)30265-X.","journal-title":"Lancet Respir Med"},{"key":"793_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.rmed.2017.12.006","volume":"134","author":"P Korenblat","year":"2018","unstructured":"Korenblat P, Kerwin E, Leshchenko I, et al. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respir Med. 2018;134:143\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2017.12.006.","journal-title":"Respir Med"},{"issue":"10","key":"793_CR42","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695\u2013709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"793_CR43","doi-asserted-by":"publisher","DOI":"10.7573\/DIC.2020-2-3","author":"S Ferreira","year":"2020","unstructured":"Ferreira S, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/DIC.2020-2-3.","journal-title":"Drugs Context."},{"issue":"5","key":"793_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40257-021-00613-8","volume":"22","author":"E Freitas","year":"2021","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625\u201338. https:\/\/doi.org\/10.1007\/s40257-021-00613-8.","journal-title":"Am J Clin Dermatol"},{"key":"793_CR45","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1104a145","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept. 2021. https:\/\/doi.org\/10.5826\/dpc.1104a145.","journal-title":"Dermatol Pract Concept."},{"key":"793_CR46","unstructured":"ClinicalTrials.gov. A study to evaluate safety and effectiveness of cendakimab (CC-93538) in participants with moderate to severe atopic dermatitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04800315. Accessed 4 Apr 2023."},{"key":"793_CR47","doi-asserted-by":"crossref","unstructured":"Okragly A, Wulur I, Daniels M et al. Characterization of binding, neutralization, and internalization of the IL-13 binding antibody lebrikizumab. Presented at 7th SPIN Congress; 2022; P054. Paris, France.","DOI":"10.1007\/s13555-023-00947-7"},{"key":"793_CR48","unstructured":"Okragly A, Ryuzoji A, Daniels M, Patel C, Benschop R. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab primary human cell assays-IL-13 induced periostin. Presented at Inflammatory Skin Disease Summit; Nov 2021; P#89. Virtual\/New York, USA."},{"key":"793_CR49","doi-asserted-by":"crossref","unstructured":"Wulur I, Van Horn RD, Ryuzoji A et al. Lebrikizumab allows Interleukin (IL)-13 membrane binding and subsequent internalization through IL-13 receptor alpha 2 (R\u03b12) (IL-13 Decoy Receptor). Presented at Inflammatory Skin Disease Summit; Nov 2021; P#96. Virtual\/New York, USA.","DOI":"10.26226\/m.62fa0091165d7b0019592ac8"},{"key":"793_CR50","unstructured":"ClinicalTrials.gov. A study of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis previously treated with dupilumab. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05369403. Accessed 4 Apr 2023."},{"key":"793_CR51","unstructured":"ClinicalTrials.gov. A study of lebrikizumab to assess the safety and efficacy of adult and adolescent participants with moderate-to-severe atopic dermatitis and skin of color. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05372419. Accessed 4 Apr 2023."},{"key":"793_CR52","unstructured":"ClinicalTrials.gov. A study of lebrikizumab in combination with topical corticosteroids in participants having atopic dermatitis (ad) that are not adequately controlled or non-eligible for cyclosporine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05149313. Accessed 4 Apr 2023."},{"key":"793_CR53","unstructured":"ClinicalTrials.gov. A study of lebrikizumab (LY3650150) in combination with topical corticosteroids in Japanese participants with moderate-to-severe atopic dermatitis (ADhere-J). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04760314. Accessed 4 Apr 2023."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00793-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T02:20:17Z","timestamp":1693016417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00793-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"11 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DB, TB, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Open access funding provided by FCT|FCCN (b-on).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Diana Bernado has no conflicts of interest. Thomas Bieber was speaker and\/or consultant and\/or Investigator for AbbVie, Affibody, Almirall, AnaptysBio, Arena, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Boehringer Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, DIECE Therapeutics, Domain Therapeutics, EQRx, Galderma, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L\u2019Or\u00e9al, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi\/Regeneron, and UCB. He is founder and chairman of the board of the non-profit biotech \u201cDavos Biosciences.\u201d Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}